| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-05 | Press release | Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-02 | Deck | Corporate Presentation |
| 2026-07-22 | Press release | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-22 | Press release | Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026 |
| 2026-07-14 | Press release | Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-13 | Press release | Geron Announces Appointment of Chinmaya Rath as Chief Business Officer |
| 2026-06-18 | Press release | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-01 | Document | Updated protocol: IMproveMF, a Phase 1b trial of imetelstat+ruxolitinib in patients with intermediate-1/2 or high-risk myelofibrosis |
| 2026-06-01 | Press release | Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference |
| 2026-05-27 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-22 | Document | Real-world Outcomes of Imetelstat: Interrogating Safety, Efficacy and Predictors of Response in Heavily Pretreated Lower-Risk MDS Patients |
| 2026-05-18 | Press release | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-12 | Press release | First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 |
| 2026-05-06 | Press release | Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-22 | Press release | Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026 |
| 2026-04-13 | Press release | Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary |
| 2026-04-07 | Proxy | Definitive proxy statement |
| 2026-04-06 | Press release | Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference |
| 2026-03-26 | Press release | Geron Announces Appointment of New Members to its Board of Directors |
| 2026-03-26 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-18 | Press release | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-02 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-25 | Press release | Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights |
| 2026-02-25 | Press release | Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights |
| 2026-02-25 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-23 | Press release | Geron Plans to Present at Upcoming Investor Conferences |
| 2026-02-11 | Press release | Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on |
| 2026-01-12 | Press release | Geron Corporation Provides 2026 Financial Guidance |
| 2026-01-12 | 8-K | Form 8-K, Item 7.01 |
| 2026-01-09 | Document | Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat |
| 2026-01-06 | 8-K | Form 8-K, Item 1.01 |
| 2025-12-31 | Document | Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS |
| 2025-12-16 | 8-K | Form 8-K, Item 2.05 |
| 2025-12-12 | Document | No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes |
| 2025-12-05 | Document | Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge |
| 2025-12-05 | Document | A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or |